Viracta Therapeutics, Inc. (VIRX)

Viracta Therapeutics, Inc. operates as a precision oncology firm, specializing in the development of therapeutic agents aimed at treating cancers linked to viral infections. The company's leading drug candidate, Nana-val (a combination of nanatinostat and valganciclovir), is currently advancing through multiple clinical trials. It is in Phase II development for Epstein-Barr virus-positive (EBV+) lymphoma. Furthermore, Nana-val is being evaluated in an open-label Phase 2 basket trial, which targets various forms of relapsed/refractory EBV+ lymphoma, and an open-label Phase 1b/2 trial for EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Beyond its flagship program, Viracta's pipeline features vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor, and VRx-510 (previously known as SNS-510), a PDK-1 inhibitor in its preclinical phase. The company is actively exploring opportunities for development and potential collaborations, particularly for vecabrutinib in conjunction with chimeric antigen receptor (CAR) T-cell therapies, and for VRx-510 across diverse oncological indications. Established in 1998, the company changed its name from Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. on February 25, 2021. Its corporate headquarters are located in Cardiff-by-the-Sea, California.

No mergers or acquisitions recorded for this company.